NEW YORK (January 16, 2020)—Non-profit drug developer TB Alliance has granted Shenyang Hongqi Pharmaceuticals Co., Ltd. (“Hongqi Pharma”), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196.SH; 02196.HK) a license to market the anti-TB medicine pretomanid as part of the three-drug “BPaL” regimen. Hongqi has agreed to commercialize the anti-tuberculosis (TB) medicine in the People’s Republic of China.
“TB Alliance is proud to partner with the leading TB medicine manufacturer in China to help ensure this treatment is available and accessible to appropriate TB patients throughout China,” said Mel Spigelman, president and CEO of TB Alliance. “We are committed to ensuring an affordable and sustainable market for all tuberculosis therapies we develop.”
“It is a great honor to partner with TB Alliance. We have the same goal of providing the latest treatments to Chinese TB patients,” said Yang Bo, general manager of Hongqi Pharma. “Hongqi pharma is committed to continuously provide high-quality, affordable therapy to this population.”
The partnership with Hongqi is part of TB Alliance’s global commercialization strategy for pretomanid as part of the BPaL regimen. This agreement is meant to complement the previously-announced partnerships with Mylan and Macleods Pharmaceuticals for the commercialization of pretomanid as part of the BPaL regimen in other countries.
About TB Alliance TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Cystic Fibrosis Foundation, European & Developing Countries Clinical Trials Partnership, Germany’s Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, Rockefeller Foundation, United Kingdom Department for International Development, and the United States Agency for International Development.
About Fosun Pharma Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) is a leading healthcare group in the PRC. Fosun Pharma adheres to the mission of bringing better health for families worldwide, with its business strategically covering the entire healthcare industry chain, including pharmaceutical manufacturing and R&D, healthcare services, medical devices and diagnosis, as well as pharmaceutical distribution and retail. Among which, pharmaceutical manufacturing and R&D are the core of its business, while healthcare services are the development focus. For more information of the company, please visit its official website: www.fosunpharma.com